Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA NASDAQ:DAWN NASDAQ:HRTX NASDAQ:KALV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$2.95-1.3%$3.43$1.24▼$4.08$792.78M1.023.81 million shs2.25 million shsDAWNDay One Biopharmaceuticals$7.12-3.4%$6.89$5.64▼$16.76$754.92M-1.251.05 million shs671,274 shsHRTXHeron Therapeutics$1.26-1.6%$1.63$1.04▼$2.68$234.64M1.221.46 million shs1.40 million shsKALVKalVista Pharmaceuticals$14.01-5.4%$14.14$7.30▼$17.28$745.53M-0.1889,385 shs2.23 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics-1.34%-0.34%-10.61%-17.13%+104.86%DAWNDay One Biopharmaceuticals-3.39%-5.70%+14.65%+6.75%-49.47%HRTXHeron Therapeutics-1.56%-3.82%-10.00%-34.72%-30.39%KALVKalVista Pharmaceuticals-5.40%-11.44%+11.28%+8.10%+30.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$2.95-1.3%$3.43$1.24▼$4.08$792.78M1.023.81 million shs2.25 million shsDAWNDay One Biopharmaceuticals$7.12-3.4%$6.89$5.64▼$16.76$754.92M-1.251.05 million shs671,274 shsHRTXHeron Therapeutics$1.26-1.6%$1.63$1.04▼$2.68$234.64M1.221.46 million shs1.40 million shsKALVKalVista Pharmaceuticals$14.01-5.4%$14.14$7.30▼$17.28$745.53M-0.1889,385 shs2.23 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics-1.34%-0.34%-10.61%-17.13%+104.86%DAWNDay One Biopharmaceuticals-3.39%-5.70%+14.65%+6.75%-49.47%HRTXHeron Therapeutics-1.56%-3.82%-10.00%-34.72%-30.39%KALVKalVista Pharmaceuticals-5.40%-11.44%+11.28%+8.10%+30.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.00Buy$6.75128.81% UpsideDAWNDay One Biopharmaceuticals 3.13Buy$25.29255.14% UpsideHRTXHeron Therapeutics 2.33Hold$4.50257.14% UpsideKALVKalVista Pharmaceuticals 3.11Buy$26.4388.64% UpsideCurrent Analyst Ratings BreakdownLatest HRTX, KALV, AKBA, and DAWN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$28.009/12/2025KALVKalVista PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$27.00 ➝ $28.008/18/2025DAWNDay One BiopharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$25.008/13/2025AKBAAkebia TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/12/2025HRTXHeron TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell8/8/2025HRTXHeron TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $3.008/6/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $16.008/6/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$36.00 ➝ $25.007/8/2025KALVKalVista PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$19.00 ➝ $27.007/8/2025KALVKalVista PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $27.007/7/2025KALVKalVista PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$18.00 ➝ $20.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$160.18M4.88N/AN/A($0.23) per share-12.83DAWNDay One Biopharmaceuticals$131.16M5.56N/AN/A$4.99 per share1.43HRTXHeron Therapeutics$144.29M1.60N/AN/A($0.22) per share-5.73KALVKalVista PharmaceuticalsN/AN/AN/AN/A$1.92 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$69.41M-$0.17N/AN/AN/A-17.91%N/A-13.47%11/6/2025 (Estimated)DAWNDay One Biopharmaceuticals-$95.50M-$0.95N/AN/AN/A-50.63%-19.01%-16.99%10/29/2025 (Estimated)HRTXHeron Therapeutics-$13.58M-$0.02N/AN/AN/A-0.62%N/A-0.40%11/11/2025 (Estimated)KALVKalVista Pharmaceuticals-$183.44M-$3.94N/AN/AN/AN/A-162.69%-88.61%N/ALatest HRTX, KALV, AKBA, and DAWN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/11/2025Q1 2026KALVKalVista Pharmaceuticals-$0.91-$1.12-$0.21-$1.12$1.97 million$1.43 million8/8/2025Q2 2025HRTXHeron Therapeutics-$0.01-$0.02-$0.01-$0.02$38.08 million$37.20 million8/5/2025Q2 2025DAWNDay One Biopharmaceuticals-$0.35-$0.29+$0.06-$0.29$35.55 million$33.91 million7/10/2025Q4 2025KALVKalVista Pharmaceuticals-$0.83-$3.69-$2.86-$0.99$4.20 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.611.981.84DAWNDay One BiopharmaceuticalsN/A9.659.53HRTXHeron TherapeuticsN/A0.820.53KALVKalVista PharmaceuticalsN/A5.355.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%DAWNDay One Biopharmaceuticals87.95%HRTXHeron Therapeutics80.01%KALVKalVista PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%DAWNDay One Biopharmaceuticals6.20%HRTXHeron Therapeutics5.86%KALVKalVista Pharmaceuticals4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430265.14 million257.19 millionOptionableDAWNDay One Biopharmaceuticals60102.43 million96.08 millionOptionableHRTXHeron Therapeutics300183.32 million172.57 millionOptionableKALVKalVista Pharmaceuticals10050.34 million48.18 millionOptionableHRTX, KALV, AKBA, and DAWN HeadlinesRecent News About These CompaniesKalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Up - Time to Buy?September 13 at 10:57 AM | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Announces Earnings ResultsSeptember 13 at 9:11 AM | marketbeat.comKalVista Pharmaceuticals, Inc. $KALV Shares Bought by Woodline Partners LPSeptember 13 at 4:36 AM | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Shares Down 4.4% on Disappointing EarningsSeptember 13 at 2:19 AM | americanbankingnews.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Q1 2026 Earnings Call TranscriptSeptember 12 at 8:51 AM | insidermonkey.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Q1 2026 Earnings Call TranscriptSeptember 12 at 8:28 AM | msn.comKalVista Pharmaceuticals Inc (KALV) Q1 2026 Earnings Call Highlights: EKTERLY Launch Drives ...September 12 at 8:28 AM | finance.yahoo.comKalVista Pharmaceuticals Reports Strong Start for EKTERLY LaunchSeptember 11 at 12:11 AM | tipranks.comBenjamin Palleiko Sells 7,294 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) StockSeptember 11 at 8:57 PM | marketbeat.comKalVista Pharmaceuticals’ Earnings Call Highlights EKTERLY SuccessSeptember 11 at 8:11 PM | tipranks.comKalVista Pharmaceuticals, Inc. (KALV) Q1 2026 Earnings Call TranscriptSeptember 11 at 12:01 PM | seekingalpha.comKalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue EstimatesSeptember 11 at 9:06 AM | zacks.comKalVista Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationSeptember 11 at 9:00 AM | seekingalpha.comEarnings Scheduled For September 11, 2025September 11 at 7:22 AM | benzinga.comKalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial ResultsSeptember 11 at 7:22 AM | finance.yahoo.comKalVista Pharmaceuticals (NASDAQ:KALV) Hits New 52-Week High - Here's What HappenedSeptember 10 at 4:53 PM | marketbeat.comInsider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells 7,294 Shares of StockSeptember 10 at 6:42 AM | insidertrades.comAdage Capital Partners GP L.L.C. Sells 24,000 Shares of KalVista Pharmaceuticals, Inc. $KALVSeptember 9, 2025 | marketbeat.comParkman Healthcare Partners LLC Takes $8.70 Million Position in KalVista Pharmaceuticals, Inc. $KALVSeptember 8, 2025 | marketbeat.comInvesco Ltd. Boosts Stake in KalVista Pharmaceuticals, Inc. $KALVSeptember 8, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (KALV) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeptember 7, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHRTX, KALV, AKBA, and DAWN Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$2.95 -0.04 (-1.34%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.95 0.00 (-0.14%) As of 09/12/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Day One Biopharmaceuticals NASDAQ:DAWN$7.12 -0.25 (-3.39%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.12 0.00 (-0.07%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Heron Therapeutics NASDAQ:HRTX$1.26 -0.02 (-1.56%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.29 +0.03 (+2.38%) As of 09/12/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.KalVista Pharmaceuticals NASDAQ:KALV$14.01 -0.80 (-5.40%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$13.94 -0.06 (-0.46%) As of 09/12/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
